Also trades as: 0QZM.L (LSE) · $vol 0M · AXP.DE (XETRA) · $vol 0M

$182.50

Last traded 2021-07-20 — delisted

NASDAQ · Healthcare · Biotechnology

Revenue

$6.1B +21.6% ▲

5Y CAGR: +18.4%

Gross Profit

$5.5B +20.0% ▲

5Y CAGR: +18.4%

Operating Income

$2.9B +33.6% ▲

5Y CAGR: +33.2%

Net Income

$603M -74.9% ▼

5Y CAGR: +33.1%

EPS (Diluted)

$2.75 -74.3% ▼

5Y CAGR: +32.6%

EBITDA

$1.0B -61.9% ▼

5Y CAGR: +7.1%

View Full Income Statement

Line Item	FY2016	FY2017	FY2018	FY2019	FY2020
Revenue	$3.1B	$3.6B	$4.1B	$5.0B	$6.1B
YoY Growth	+18.4%	+15.1%	+16.3%	+20.8%	+21.6%
Cost of Revenue	$258M	$454M	$374M	$394M	$554M
Gross Profit	$2.8B	$3.1B	$3.8B	$4.6B	$5.5B
Gross Margin	91.6%	87.2%	90.9%	92.1%	90.9%
R&D Expenses	$757M	$878M	$730M	$886M	$1.0B
SG&A Expenses	$954M	$1.1B	$1.1B	$1.3B	$1.4B
Operating Expenses	$2.0B	$2.3B	$2.2B	$2.5B	$2.7B
Operating Income	$793M	$804M	$1.6B	$2.1B	$2.9B
Operating Margin	25.7%	22.6%	38.6%	42.9%	47.1%
Interest Expense	$97M	$98M	$98M	$78M	$105M
Income Before Tax	$576M	$548M	$242M	$2.2B	$569M
Tax Expense	$177M	$104M	$165M	-$226M	-$34M
Net Income	$399M	$443M	$78M	$2.4B	$603M
Net Margin	12.9%	12.5%	1.9%	48.2%	9.9%
EPS (Diluted)	$1.76	$1.97	$0.35	$10.70	$2.75
EBITDA	$1.1B	$1.1B	$746M	$2.6B	$1.0B
Shares Outstanding	227M	225M	224M	225M	219M

Line Item	FY2019 Q2	FY2019 Q3	FY2019 Q4	FY2020 Q1	FY2020 Q2	FY2020 Q3	FY2020 Q4	FY2021 Q1
Revenue	$1.2B	$1.3B	$1.4B	$1.4B	$1.4B	$1.6B	$1.6B	$1.6B
Cost of Revenue	$99M	$95M	$114M	$112M	$145M	$145M	$152M	$125M
Gross Profit	$1.1B	$1.2B	$1.3B	$1.3B	$1.3B	$1.4B	$1.4B	$1.5B
Gross Margin	91.8%	92.5%	91.7%	92.3%	90.0%	90.9%	90.4%	92.3%
R&D Expenses	$188M	$233M	$270M	$201M	$221M	$286M	$295M	$289M
SG&A Expenses	$299M	$299M	$381M	$320M	$301M	$334M	$444M	$343M
Operating Expenses	$567M	$608M	$724M	$594M	$596M	$673M	$793M	$685M
Operating Income	$537M	$560M	$546M	$739M	$704M	$771M	$647M	$636M
Operating Margin	44.6%	44.3%	39.4%	51.1%	48.7%	48.5%	40.6%	38.9%
Interest Expense	$18M	$18M	$22M	$26M	$24M	$28M	$28M	$27M
Income Before Tax	$500M	$536M	$602M	$664M	-$1.4B	$667M	$591M	$603M
Tax Expense	$40M	$68M	-$287M	$106M	-$284M	$89M	$55M	$113M
Net Income	$460M	$468M	$889M	$558M	-$1.1B	$578M	$536M	$636M
Net Margin	38.2%	37.0%	64.2%	38.6%	-73.9%	36.4%	33.7%	38.9%
EPS (Diluted)	$2.04	$2.08	$4.00	$2.50	$-4.84	$2.62	$2.45	$2.86
EBITDA	$614M	$646M	$714M	$779M	-$1.2B	$770M	$693M	$705M
Shares Outstanding	226M	224M	222M	223M	221M	221M	219M	223M

ALXN NASDAQ